18F-Fluorodeoxyglucose Positron Emission Tomography for the Detection of Myocardial Inflammation in Arrhythmogenic Left Ventricular Cardiomyopathy

Tessier, Roxane; Marteau, Lara; Vivien, Marc; Guyomarch, Béatrice; Thollet, Aurélie; Fellah, Imen; Jamet, Bastien; Sébille, Jean Charles; Eugène, Thomas; Serfaty, Jean Michel; Probst, Vincent; Trochu, Jean Noël; Toquet, Claire; Warin-Fresse, K.; Meneveau, Nicolas

doi:10.1161/circimaging.122.014065

Cited by 7 publications

(4 citation statements)

References 5 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies, including our own group’s 2 have demonstrated 18 fluorodeoxyglucose ( 18 FDG) avidity on positron emission tomography scan among patients with genetic cardiomyopathy. Interestingly, none of the 16 endomyocardial biopsies (EMBs) in these prior studies demonstrated M-Infl, 2 , 3 , 4 , 5 whereas all EMBs in the present study demonstrated at least low-level M-Infl. We propose several mechanisms that may explain this discrepancy: Peretto et al 1 may have biopsied more “nontraditional” EMB sites, whereas our study used electroanatomic mapping voltage guidance, and our EMBs (and likely those of prior studies) were restricted to the right ventricular septum, which does not always contain the highest 18 FDG avidity.…”

contrasting

confidence: 64%

Nonischemic Cardiomyopathy

Bevan,

Lal,

Nazer

2023

JACC: Basic to Translational Science

View full text Add to dashboard Cite

contrasting

confidence: 64%

Nonischemic Cardiomyopathy

Bevan,

Lal,

Nazer

2023

JACC: Basic to Translational Science

View full text Add to dashboard Cite

“…In a recent study, patients with DSP cardiomyopathy had an 18-FDG PET-positive scan in 59% of cases. Of these, 70% had focal uptake and 30% diffuse uptake [ 35 ].…”

Section: Cardiac Nuclear Imagingmentioning

confidence: 99%

Multimodality Imaging in Arrhythmogenic Left Ventricular Cardiomyopathy

Monda

Rubino

Palmiero

et al. 2023

JCM

View full text Add to dashboard Cite

The term arrhythmogenic cardiomyopathy (ACM) describes a large spectrum of myocardial diseases characterized by progressive fibrotic or fibrofatty replacement, which gives the substrate for the occurrence of ventricular tachyarrhythmias and the development of ventricular dysfunction. This condition may exclusively affect the left ventricle, leading to the introduction of the term arrhythmogenic left ventricular cardiomyopathy (ALVC). The clinical features of ALVC are progressive fibrotic replacement with the absence or mild dilation of the LV and the occurrence of ventricular arrhythmias within the left ventricle. In 2019, the diagnostic criteria for the diagnosis of ALVC, based on family history and clinical, electrocardiographic, and imaging features, have been proposed. However, since the significant clinical and imaging overlap with other cardiac diseases, genetic testing with the demonstration of a pathogenic variant in an ACM-related gene is required for diagnostic confirmation. In ALVC, the multimodality imaging approach comprises different imaging techniques, such as echocardiography, cardiac magnetic resonance, and cardiac nuclear imaging. It provides essential information for the diagnosis, differential diagnosis, sudden cardiac death risk stratification, and management purposes. This review aims to elucidate the current role of the different multimodality imaging techniques in patients with ALVC.

show abstract

“…Only in carriers of desmoplakin (DSP) gene variants, characterized by predominant LV involvement and by recurrent episodes of acute chest pain associated with myocardial injury and/or ventricular arrhythmias, 18-FDG PET may improve the assessment of inflammatory “warm phase”, which represents the early pre-phenotypic stage of ACM [ 58 ]. According to a recent study, patients with DSP-related cardiomyopathy usually demonstrate an 18-FDG PET-positive scan in 59% of cases, in terms of focal (70%) or diffuse (30%) uptake; in this sense, it has been suggested to apply FDG-PET as a method to differentiate diagnosis in the context of ACM phenocopies, such as myocarditis, cardiac sarcoidosis, and other immune-mediated diseases [ 59 , 60 , 61 ].…”

Section: The Hierarchical and Multiparametric Approach Of Scd Risk Es...mentioning

confidence: 99%

Personalized Management of Sudden Death Risk in Primary Cardiomyopathies: From Clinical Evaluation and Multimodality Imaging to Ablation and Cardioverter-Defibrillator Implant

Lazzeroni,

Crocamo,

Ziveri

et al. 2023

JPM

View full text Add to dashboard Cite

Sudden cardiac death represents the leading cause of death worldwide; although the majority of sudden deaths occur in an elderly population with coronary artery disease, some occur in young and otherwise healthy individuals, as is the case of cardiomyopathies. The aim of the present review is to provide a stepwise hierarchical approach for the global sudden death risk estimation in primary cardiomyopathies. Each individual risk factor is analyzed for its contribution to the overall risk of sudden death for each specific cardiomyopathy as well as across all primary myocardial diseases. This stepwise hierarchical and personalized approach starts from the clinical evaluation, subsequently passes through the role of electrocardiographic monitoring and multimodality imaging, and finally concludes with genetic evaluation and electro-anatomical mapping. In fact, the sudden cardiac death risk assessment in cardiomyopathies depends on a multiparametric approach. Moreover, current indications for ventricular arrhythmia ablation and defibrillator implantation are discussed.

show abstract

18F-Fluorodeoxyglucose Positron Emission Tomography for the Detection of Myocardial Inflammation in Arrhythmogenic Left Ventricular Cardiomyopathy

Cited by 7 publications

References 5 publications

Nonischemic Cardiomyopathy

Nonischemic Cardiomyopathy

Multimodality Imaging in Arrhythmogenic Left Ventricular Cardiomyopathy

Personalized Management of Sudden Death Risk in Primary Cardiomyopathies: From Clinical Evaluation and Multimodality Imaging to Ablation and Cardioverter-Defibrillator Implant

Contact Info

Product

Resources

About